Daclizumab

CHEMBL1201605 Phase 4 已批准 Antibody
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A humanized monoclonal antibody against the IL-2 receptor alpha subunit (CD25) that modulates immune activity, formerly approved for relapsing multiple sclerosis but withdrawn from the market due to serious inflammatory brain reactions. It was also used as an immunosuppressant in organ transplantation.

治疗领域

作用机制

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A humanized monoclonal antibody against the IL-2 receptor alpha subunit (CD25) that modulates immune activity, formerly approved for relapsing multiple sclerosis but withdrawn from the market due to serious inflammatory brain reactions. It was also used as an immunosuppressant in organ transplantation.

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Yes, Daclizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201605. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.